Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa
Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Saarland University Hospital, Homburg (Saar), Saarland, Germany.
BMJ Open. 2021 Oct 12;11(10):e054994. doi: 10.1136/bmjopen-2021-054994.
Peripartum cardiomyopathy (PPCM) remains a major contributor to maternal morbidity and mortality worldwide. The disease is associated with various complications, which occur predominantly during the early stages of the disease. Adverse outcomes include decompensated heart failure, thromboembolic complications, arrhythmias and death. We present a protocol for a systematic review and meta-analysis to summarise the available data on the complications and outcomes of women with PPCM.
A comprehensive search of all articles published between 2000 (the year in which the first universal definition of PPCM was used) and 1 June 2021 will be performed on PubMed/MEDLINE, Web of Science, Scopus and EBSCO Host, including Academic Search Premier, Africa-Wide Information, Cumulative Index to Nursing and Allied Health Literature. All cohort and cross-sectional studies, as well as control arms of randomised control trials (RCTs) reporting on the complications and outcomes of PPCM will be included in the review. Methodological quality assessment of included studies will be done by assessing the risk of bias. Heterogeneity of the data will be tested by visual inspection of the forest plot and I and χ tests. This study will report the burden of complications occurring around the time of diagnosis as well as the 6-month or 12-month outcomes of women with PPCM. A summarised description in form of a pooled analysis of across multiple centres, regions and continents would help us to better understand the estimates of complications and outcomes of women with PPCM.
As this research is a systematic review of published literature, ethical approval is not required. The results will be reported according to the latest guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement, and will be submitted to a peer-reviewed journal.
CRD42021255654.
围生期心肌病（PPCM）仍然是全球孕产妇发病率和死亡率的主要原因。该疾病与各种并发症相关，这些并发症主要发生在疾病的早期阶段。不良结局包括心力衰竭失代偿、血栓栓塞并发症、心律失常和死亡。我们提出了一项系统评价和荟萃分析的方案，以总结 PPCM 妇女并发症和结局的现有数据。
将在 2000 年（首次使用 PPCM 的通用定义的那一年）至 2021 年 6 月 1 日期间发表的所有文章在 PubMed/MEDLINE、Web of Science、Scopus 和 EBSCO Host 上进行全面搜索，包括 Academic Search Premier、Africa-Wide Information、Cumulative Index to Nursing and Allied Health Literature。所有队列和横断面研究，以及报告 PPCM 并发症和结局的随机对照试验（RCT）的对照臂都将包括在综述中。通过评估偏倚风险来对纳入研究的方法学质量进行评估。通过视觉检查森林图和 I 和 χ 检验来测试数据的异质性。本研究将报告诊断时周围并发症的负担，以及 PPCM 妇女的 6 个月或 12 个月结局。通过对多个中心、地区和大陆的综合分析进行总结描述，将有助于我们更好地了解 PPCM 妇女并发症和结局的估计值。
由于这是对已发表文献的系统评价研究，因此不需要伦理批准。结果将按照最新的系统评价和荟萃分析 2020 声明的首选报告项目进行报告，并将提交给同行评议的期刊。
PROSPERO 注册号：CRD42021255654。
